1. Introduction {#sec1}
===============

Malignant otitis externa (MOE) remains a relatively uncommon condition but can lead to serious morbidity or mortality as diagnosis is often delayed leading to initially ineffective treatment \[[@B1]\]. The infection begins in the external auditory canal, typically presenting with severe otalgia and purulent otorrhoea; it can rapidly spread via the ear canal soft tissue to the temporal bone resulting in osteomyelitis and subsequent cranial nerve palsies and intracranial infection. The prevalence of bacterial MOE is not accurately documented \[[@B2]\] and it is unknown whether fungal MOE is a repercussion of unsuccessfully treated bacterial otitis externa or if it represents a *de novo* presentation of fungal disease.

The most commonly reported pathogen in malignant otitis externa is *Pseudomonas aeruginosa* \[[@B2]\]. *Aspergillus*species and *Candida albicans* have been implicated in fungal MOE. There are 32 previously reported cases of fungal MOE, usually occurring in patients with some form of immunosuppression---typically diabetes, acquired immunodeficiency, or malignancy. We present a case of fungal malignant otitis externa complicated by a facial nerve palsy that proved very difficult to achieve a formal diagnosis.

2. Case {#sec2}
=======

An 83-year-old man with type 2 diabetes presented with right sided otalgia and otorrhoea; examination revealed granulation tissue inferiorly in his ear canal at the Osseochondral junction. A clinical diagnosis of malignant otitis externa was made. *Pseudomonas aeruginosa* was grown on microbiological culture of the discharge, sensitive to ciprofloxacin. His condition was successfully treated over a period of three months with oral and topical ciprofloxacin and he was discharged from clinic pain-free with an otoscopically normal canal.

One year later, he presented with left-sided grade III facial nerve palsy and a painful left ear (note this is the contralateral side to the original presentation). The left ear was initially otoscopically normal. CT and MR imaging demonstrated a left skull base osteomyelitis with involvement of the temporal bone and extension to the clivus with an associated small epidural abscess. Over the next few months, the VII nerve palsy progressed to complete paralysis (grade VI) and was unresponsive to treatment with ciprofloxacin and meropenem. He developed inflammation of his left external canal with an associated otorrhoea. Numerous aural swabs revealed no definitive microbiological diagnosis. Tissue biopsies were taken directly from the canal and, in contrast to the previous microbiology, *Aspergillus flavus* was isolated. Treatment was commenced with intravenous voriconazole for 2 weeks, followed by subsequent conversion to oral voriconazole. Within a month of commencing antifungal therapy, he became pain-free and his facial palsy resolved completely. Oral voriconazole therapy was continued for 10 months after resolution of symptoms. The initial plan had been to treat him for 12 months, although the patient developed worsening liver function; hence, the therapy was discontinued.

3. Discussion {#sec3}
=============

Cranial nerve palsies are frequently seen in fungal MOE \[[@B3]\]; however, many reported cases have not demonstrated a significant improvement following treatment, possibly due to the delayed isolation of the pathogen and initiation of antifungal treatment. Halsey et al. \[[@B3]\] reported the presence of VII nerve palsy in 75% of patients with *Aspergillus* infection, compared with only 34% in MOE due to *Pseudomonas*.

*Aspergillus fumigatus* was thought to be the most common fungal pathogen in MOE \[[@B4]\], with *Aspergillus flavus* assumed to be a less frequent cause of the condition. However, review of published cases reveals *A. flavus* to be a roughly as prevalent as *A. flavus* in MOE. *A. flavus* has been observed to be 100 times more virulent than *A. fumigatus* and has an optimum temperature for growth of 37°C, which may explain its particular pathogenicity in humans \[[@B5]\].

In MOE, the infection spreads through the fissures of Santorini, small perforations in the cartilaginous floor of the external auditory canal, and then medially until it reaches the skull base \[[@B1]\]. Here, it causes bony destruction and further continues its medial progression triggering cranial nerve palsies with the VII nerve being most commonly affected due to the proximity of the stylomastoid foramen to the ear canal. The presence of a facial nerve palsy has been suggested to represent a poor prognosis in patients with MOE along with coexisting immunosuppression \[[@B6]\]. [Table 1](#tab1){ref-type="table"} summarizes the cases of fungal MOE (FMOE) present in the literature.

4. Summary of the Literature {#sec4}
============================

The mean age of patients in the literature was 52 years with a male : female ratio of 7 : 3. *Aspergillus* species were the most commonly implicated pathogens. The most frequently occurring comorbidity was diabetes mellitus but haematological malignancy and acquired immunodeficiency were also recognized. 44% (14/32) of patients were reported to have an associated cranial nerve palsy and 29% (4/14) of these did not resolve following treatment. There was limited information on total duration of treatment for most of the reported cases. Amphotericin B and itraconazole were favoured for treatment of FMOE in the earlier case reports, whereas voriconazole has played a role in the treatment of the majority of reported cases since 2008. The mortality rate of FMOE was 15% (5/32).

Voriconazole is currently recommended as first line treatment in cases of invasive aspergillosis \[[@B31]\] and its use is increasing since its launch in 2002. The intravenous form is recommended for use in systemically unwell patients, with the oral form being reserved for those who are stable or have improved following initial intravenous treatment. Voriconazole is widely distributed throughout tissues and, in its oral form, is not usually associated with worsening of renal function. This is particularly important as it is often patients with comorbidities affecting renal function such as diabetes, who develop aspergillosis FMOE and therefore require treatment with voriconazole.

The most commonly reported side effects of voriconazole include visual disturbance, particularly to colour vision, abnormal liver function tests, deranged renal function, and electrolyte abnormalities \[[@B32]\]. As noted in the literature, amphotericin B was most frequently used, although it has a significantly poorer side effect profile, including derangement of renal function \[[@B8]\]. Itraconazole and caspofungin have also been used in cases reported in the literature.

Antibiotic therapy for the majority of cases of MOE is guided by the results of aural swabs sent for microbiological culture. Diagnosis of FMOE in our case and other cases in the literature required formal tissue sampling from the external auditory canal in order to identify the pathogen \[[@B3], [@B22], [@B33]\].

The patient in our case presented one year following treatment of bacterial MOE with symptoms in the contralateral ear. Although we found no evidence that the causative organism was the same on both sides, we note one particular case in the literature where the disease spread from one side to the other via the clivus \[[@B31]\].

5. Conclusion {#sec5}
=============

We would recommend biopsy of tissue from the external auditory canal in any patient with a presumed diagnosis of MOE in addition to aural swabs. The importance of this is to obtain early confirmation of a fungal pathogen thereby allowing timely treatment to be commenced.
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Summary of published cases of FMOE. M: male, F: female, DM: diabetes mellitus, N: no, Y: yes, NIDDM: noninsulin-dependent diabetes mellitus, AML: acute myeloid leukaemia, tx: transplant, CRF: chronic renal failure, HTN: hypertension, AIDS: acquired immunodeficiency syndrome, and ALL: acute lymphocytic leukaemia. Numbers in round brackets represent separate patients reported in the same paper.

  Main author                              Year of paper   Age (years)   M/F   Relevant comorbidities          Pathogen                        Nerve palsy       Treatment                                              Surgical debridement   Symptom resolution
  ---------------------------------------- --------------- ------------- ----- ------------------------------- ------------------------------- ----------------- ------------------------------------------------------ ---------------------- ---------------------------
  Tarazi et al. (1) \[[@B7]\]              2012            77            M     Type 2 DM (poorly controlled)   *Aspergillus*                   No                Amphotericin then voriconazole                         N                      Y
  Tarazi et al. (2) \[[@B7]\]              2012            85            F     Type 2 DM (poorly controlled)   *Aspergillus*                   VII               Amphotericin then voriconazole                         N                      Y
  Tarazi et al. (3) \[[@B7]\]              2012            70            F     Type 2 DM (poorly controlled)   *Aspergillus*                   No                Voriconazole                                           N                      Y
  Halsey et al. \[[@B3]\]                  2011            62            M     AML                             *Aspergillus wentii*            VII               Amphotericin B then itraconazole                       Y                      No---CN palsies persisted
  Parize et al. (1) \[[@B8]\]              2009            48            M     Polychondritis                  *Aspergillus niger*             No                Voriconazole                                           N                      Yes
  Parize et al. (2) \[[@B8]\]              2009            40            F     IDDM, renal tx, CRF             *Aspergillus niger*             No                Voriconazole                                           Y                      N---hearing loss
  Ling and Sader \[[@B4]\]                 2008            77            M     NIDDM, HTN, gout                *Candida, Aspergillus flavus*   VII               Voriconazole, caspofungin                              Y                      Yes
  Narozny et al. \[[@B9]\]                 2006            65            M     NIDDM                           *Aspergillus*                   VII, IX, X, XII   Amphotericin B, itraconazole                           Y                      N---died
  Tzuku et al. \[[@B10]\]                  2006            17            F     IDDM                            *Scedosporium apiospermum*      No                Amphotericin B                                         Y                      No---died on day 7
  Bellini et al. \[[@B11]\]                2003            73            M     NIDDM                           *Aspergillus niger*             Unspecified       Amphotericin B then itraconazole                       N                      Yes
  Shelton et al. \[[@B12]\]                2002            58            M     Nil                             *Aspergillus niger*             Unspecified       Itraconazole                                           N                      Yes
  Finer et al. \[[@B13]\]                  2002            7             M     Neuroblastoma                   *Aspergillus flavus*            Unspecified       Amphotericin B then itraconazole                       N                      Yes
  Chai et al. \[[@B14]\]                   2000            53            M     NIDDM                           *Malassezia sympodialis*        VII, IX, X, XII   Amphotericin B then fluconazole                        N                      No---CN palsies persisted
  Chen et al. (1) \[[@B15]\]               1999            41            M     AIDS                            *Aspergillus fumigatus*         VII               Amphotericin B then itraconazole                       Y                      Yes
  Chen et al. (2) \[[@B15]\]               1999            36            M     AIDS                            Unknown                         VII               Amphotericin B                                         Y                      No---CN palsies persisted
  Slack et al. \[[@B16]\]                  1999            14            F     ALL                             *A. flavus, niger, fumigatus*   Unspecified       Amphotericin B then itraconazole                       Y                      Yes
  Muñoz and Martínez-Chamorro \[[@B17]\]   1998            27            F     AIDS                            *Aspergillus fumigatus*         Unspecified       Itraconazole then amphotericin B                       N                      N---died
  Ress et al. \[[@B18]\]                   1997            41            M     AIDS                            *Aspergillus fumigatus*         Unspecified       Timentin-gentamicin                                    N                      N---died
  Kountakis et al. \[[@B19]\]              1997            65            M     NIDDM                           *Aspergillus flavus*            VII               Amphotericin B                                         Y                      No---CN palsies persisted
  Yates \[[@B20]\]                         1997            18            M     AIDS                            *Aspergillus fumigatus*         Unspecified       Itraconazole                                           Y                      Yes
  Harley et al. \[[@B21]\]                 1995            20            M     ALL                             *Aspergillus flavus*            VII               Amphotericin B                                         Y                      N---died
  Gordon and Giddings (1) \[[@B22]\]       1994            67            F     NIDDM, HTN                      *Aspergillus flavus*            No                Amphotericin B then itraconazole                       Y                      No
  Gordon and Giddings (2) \[[@B22]\]       1994            82            M     Nil                             *Aspergillus flavus*            No                Ceftazidime, ciprofloxacin, tobramycin, itraconazole   Y                      No
  Hanna et al. \[[@B23]\]                  1993            61            M     NIDDM                           *Aspergillus flavus, Candida*   VII               Amphotericin B                                         Y                      Yes
  Reiss et al. (1) \[[@B24]\]              1991            42            M     AIDS                            *Aspergillus fumigatus*         Unspecified       Amphotericin B then itraconazole                       Y                      Yes
  Reiss et al. (2) \[[@B24]\]              1991            30            M     AIDS                            *Aspergillus fumigatus*         Unspecified       Amphotericin B then itraconazole                       Y                      Yes
  Phillips et al. \[[@B25]\]               1990            64            F     NIDDM, AML                      *Aspergillus*                   VII               Amphotericin B then itraconazole                       N                      Yes
  Menachof and Jackler \[[@B26]\]          1990            46            F     AML                             *Aspergillus flavus*            VII               Amphotericin B                                         Y                      Y
  Denning et al. \[[@B27]\]                1989            38            M     Nil                             *Aspergillus fumigatus*         No                Itraconazole                                           Y                      Yes
  Cunningham et al. \[[@B28]\]             1988            85            M     Nil                             *Aspergillus fumigatus*         VII               Amphotericin B, rifampicin                             Y                      Yes
  Bickley et al. \[[@B29]\]                1988            80            M     Myelodysplasia                  *Aspergillus*                   No                Amphotericin B                                         Y                      Yes
  Petrak et al. \[[@B30]\]                 1985            68            M     AML                             *Aspergillus fumigatus*         VII               Amphotericin B                                         Y                      No---CN palsies persisted
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